<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/263360-process-for-the-preparation-of-the-alpha-crystalline-form-of-the-arginine-salt-of-perindopril-of-compound-of-formula-i by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:13:31 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 263360:&quot; PROCESS FOR THE PREPARATION OF THE ALPHA CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL OF COMPOUND OF FORMULA (I)&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot; PROCESS FOR THE PREPARATION OF THE ALPHA CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL OF COMPOUND OF FORMULA (I)&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>&amp;#945; crystalline form of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicaments.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL,<br>
A PROCESS FOR ITS PREPARATION AND<br>
PHARMACEUTICAL COMPOSITIONS CONTAINING IT<br>
The present invention relates to the a crystalline form of the arginine salt of perindopril of formula (I):<br><br>
(Formula Removed)<br>
to a process for its preparation and to pharmaceutical compositions containing it.<br>
Perindopril and its pharmaceutically acceptable salts, and more especially its arginine salt,<br>
have valuable pharmacological properties.<br>
Their principal  property  is  that  of inhibiting  angiotensin  I  converting  enzyme  (or<br>
kininase II),  which allows,  on the one hand,  impedance  of the  conversion of the<br>
decapeptide angiotensin I to the octapeptide angiotensin II (a vasoconstrictor) and, on the<br>
other hand, prevention of the degradation of bradykinin (a vasodilator) to an inactive<br>
peptide.<br>
Those two actions contribute to the beneficial effects of perindopril in cardiovascular<br>
diseases, more especially in arterial hypertension and heart failure.<br>
Perindopril, its preparation and its use in therapeutics have been described in European Patent specification EP 0 049 658.<br>
The arginine salt of perindopril has been described in European Patent specification EP 1 354 873.<br>
In view of the pharmaceutical value of that compound, it has been of prime importance to obtain it with excellent stability, mainly in terms of hygroscopicity, of processability of the powder, of filtrability of the solid, of grindability, and of solvent retention.<br>
Obtaining a well-defined crystalline form allows those requirements to be met.<br>
Patent specification EP 1 354 873 describes the arginine salt of perindopril. That document does not, however, specify the conditions for obtaining that salt in a well-defined crystalline form.<br>
The Applicant has now found that the arginine salt of perindopril can be obtained in a well-defined crystalline form that, as a result, has valuable characteristics for filtration, drying and ease of formulation.<br>
More specifically, the present invention relates to the a crystalline form of the compound of formula (I), characterised by the following powder X-ray diffraction peaks, measured using a diffractometer with a copper anti-cathode and expressed in terms of angle 2 theta (°): 4.5, 7.9 and 13.5.<br>
Preferably, the present invention relates to the a crystalline form of the compound of formula (I), characterised by the following powder X-ray diffraction peaks, measured using a diffractometer with a copper anti-cathode and expressed in terms of angle 2 theta (°):4.5,7.9,13.5, 17.5 and 20.6.<br>
Even more preferably, the present invention relates to the a crystalline form of the compound of formula (I), characterised by the following powder X-ray diffraction diagram measured using a diffractometer (copper anti-cathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense line) :<br>
(Table Removed)<br>
The invention relates also to a process for the preparation of the a crystalline form of the compound of formula (I), wherein perindopril is dissolved in water with L-arginine, and then an apolar solvent and a polar solvent are added and the crystals obtained are filtered off, washed and then dried.<br>
Among   the   apolar   solvents   there   may   be   mentioned,   by   way   of   example,<br>
methylcyclohexane, cyclohexane and toluene.<br>
Among the polar solvents there may be mentioned, by way of example, dimethyl<br>
sulphoxide,     N,N-dimethylformamide,     N,N-dimethylacetamide     and     N-methyl-2-<br>
pyrrolidinone.<br>
The crystals so obtained are in a compact form composed of baguettes.<br>
According to one embodiment of the invention, perindopril is dissolved in water with L-arginine and then methylcyclohexane and dimethyl sulfoxide are added and the crystals obtained are filtered off, washed and then dried.<br>
The invention relates also to pharmaceutical compositions comprising as active ingredient the a crystalline form of the compound of formula (I) together with one or more appropriate, inert, non-toxic excipients. Among the pharmaceutical compositions according to the invention there may be mentioned, more especially, those that are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragees, sublingual tablets, capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions.<br>
The dosage used can be varied according to the nature and severity of the disorder, the administration route and the age and weight of the patient. It varies from 1 to 500 mg per day in one or more administrations.<br>
The pharmaceutical compositions according to the invention may also contain a diuretic such as indapamide.<br>
The following Examples illustrate the invention.<br>
The powder X-ray diffraction spectrum was measured under the following experimental conditions :<br>
Siemens D5005 diffractometer; scintillation detector;<br>
Copper anti-cathode, voltage 40KV, intensity 30mA ;<br>
Mounting θ-θ, fixed specimen;<br>
Temperature : ambient;<br>
Measurement range : 3° to 30°;<br>
Increment between each measurement: 0.04°;<br>
Measurement time per step :4 s;<br>
Fixed slits : 1.6 mm;<br>
Kß filter (Ni);<br>
No internal reference;<br>
Zeroing procedure using Siemens slits;<br>
Experimental data processed using EVA software (version 9.0).<br>
EXAMPLE 1 :   a crystalline form of perindopril arginine salt<br>
1.5 kg of water, 328 g of perindopril and 155 g of L-arginine are introduced into a reactor at ambient temperature and with stirring. When a clear solution is obtained, 630 g of methylcyclohexane are added, and then 4.7 kg of dimethyl sulphoxide are added slowly. The mixture is then stirred until the temperature of the heterogeneous mixture stabilises at around 20.0°C, after which the mixture is filtered and the solid obtained is washed and dried.<br>
The crystals so obtained are in a compact form composed of baguettes.<br>
The water content of the resulting product is approximately 3.2%, which corresponds to a<br>
monohydrate.<br>
Powder X-ray diffraction diagram :<br>
The powder X-ray diffraction profile (diffraction angles) of the a form of perindopril arginine salt is given by the significant lines collated in the following table together with the intensity and relative intensity (expressed as a percentage of the most intense line).<br>
(Table Removed)<br>
EXAMPLE 2 :   Pharmaceutical composition<br>
Preparation formula for 1000 tablets each containing 4 mg of active ingredient:<br>
Compound of Example 1	 4 g<br>
Hydroxypropylcellulose	  2 g<br>
Wheat starch	 10 g<br>
Lactose	100 g<br>
Magnesium stearate	  3 g<br>
Talc	  3 g<br><br><br><br><br><br><br><br>
CLAIMS<br>
1.	α crystalline form of the arginine salt of perindopril, of formula (I) :<br>
(Formula Removed)<br>
characterised by the following powder X-ray diffraction peaks, measured using a diffractometer with a copper anti-cathode and expressed in terms of Bragg's angle 2 theta (°) : 4.5, 7.9 and 13.5.<br>
2.	α crystalline form of the compound of formula (I) according to claim 1, characterised by the following powder X-ray diffraction peaks, measured using a diffractometer with a copper anti-cathode and expressed in terms of Bragg's angle 2 theta (°) : 4.5, 7.9, 13.5, 17.5 and 20.6.<br>
3.	α crystalline form of the compound of formula (I) according to claim 1, characterised by the following powder X-ray diffraction diagram measured using a diffractometer (copper anti-cathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense line):<br>
(Table Removed)<br>
4. Process for the preparation of the a crystalline form of the compound of formula (I) according to any one of claims 1 to 3, wherein perindopril is dissolved in water with L-arginine, and then an apolar solvent and a polar solvent are added and the crystals obtained are filtered off, washed and then dried.<br>
5. Process according to claim 4, wherein the apolar solvent is selected from methylcyclohexane, cyclohexane and toluene.<br>
S. Process according to either claim 4 or claim 5, wherein the polar solvent is selected from dimethyl sulphoxide, N,N-dimethylformamide, N,N-dimethylacetamide and N-methyl-2-pyrrolidinone.<br>
7. Process according to claim 4, wherein the apolar solvent is methylcyclohexane and the polar solvent is dimethyl sulphoxide.<br>
3. Pharmaceutical composition comprising as active ingredient the compound according to any one of claims 1 to 3, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers.<br>
9.	Pharmaceutical composition accerdins to claim 8.charaotprised in that it also contains a diuretic.<br>
10.	Pharmaceutical composition according to claim 9, characterised in that the diuretic is indapamide.<br>
11.	Use of the compound according to any one of claims 1 to 3 in the manufacture of a medicaments for use as inhibitors of angiotensin I converting enzyme.<br>
12.	Use of the compound according to any one of claims 1 to 3 in the manufacture of medicaments for use in the treatment of cardiovascular diseases.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUFic3RyYWN0LSgxMS0xMC0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Abstract-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUNsYWltcy0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Claims-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUNsYWltcy0oMjUtMDktMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Claims-(25-09-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjUtMDktMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Correspondence Others-(25-09-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Correspondence-Others-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LURlc2NyaXB0aW9uIChDb21wbGV0ZSktKDExLTEwLTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Description (Complete)-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUZvcm0tMi0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Form-2-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUZvcm0tMy0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Form-3-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUZvcm0tMy0oMjUtMDktMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Form-3-(25-09-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LUdQQS0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-GPA-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Njg2OC1kZWxucC0yMDA4LVBldGl0aW9uLTEzNy0oMTEtMTAtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6868-delnp-2008-Petition-137-(11-10-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="263359-a-process-of-manufacturing-audio-visual-detectable-temper-evident-lable.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="263361-a-device-for-carrying-out-optical-readings-on-textile-materials-submitted-to-dyeing-and-method-thereof.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>263360</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>6868/DELNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>44/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>31-Oct-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>22-Oct-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>11-Aug-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>LES LABORATOIRES SERVIER</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>12, PLACE DE LA DEFENSE, F-92415 COURBEVOIE CEDEX, FRANCE.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>GERARD COQUEREL</td>
											<td>192, RUE DE 1&#x27;EGLISE, 76520 BOOS, FRANCE.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>LOIC LEFEBVRE</td>
											<td>APT 146, 17 PARC DE LA RISLE, 76130 MONT SAINT AIGNAN, FRANCE</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JEAN-CLAUDE SOUVIE</td>
											<td>RESIDENCE GARDEN PARK B 19, AVENUE NORMAN PRINCE 64000 PAU, FRANCE</td>
										</tr>
										<tr>
											<td>4</td>
											<td>PASCALE AUTHOUART</td>
											<td>12, RUE DU VILLAGE, 76430 LES TROIS PIERRES, FRANCE</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 209/42</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR2007/000335</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-02-26</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>06/01748</td>
									<td>2006-02-28</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/263360-process-for-the-preparation-of-the-alpha-crystalline-form-of-the-arginine-salt-of-perindopril-of-compound-of-formula-i by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:13:32 GMT -->
</html>
